G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

Rhea-AI Summary

G1 Therapeutics, a commercial-stage oncology company, announced that CEO Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference on June 22 at 9:20 AM EDT. The virtual event will include a fireside chat, accessible via a live webcast on G1's website. G1 Therapeutics specializes in developing therapies for cancer patients, including their first product, COSELA™ (trilaciclib), which is being evaluated in various solid tumors like colorectal, breast, lung, and bladder cancers. For more details, visit their website.

RESEARCH TRIANGLE PARK, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference. The fireside chat will take place on June 22^nd at 9:20 AM EDT. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

FAQ

When is G1 Therapeutics participating in the Raymond James Human Health Innovation Conference?

G1 Therapeutics will participate in the conference on June 22, 2021, at 9:20 AM EDT.

Who is the CEO of G1 Therapeutics?

The CEO of G1 Therapeutics is Jack Bailey.

Where can I watch the G1 Therapeutics conference webcast?

The live webcast of the G1 Therapeutics conference can be accessed on their Events & Presentations page.

What is COSELA™ by G1 Therapeutics?

COSELA™ (trilaciclib) is G1 Therapeutics' first commercial product designed to improve the lives of cancer patients.

What cancer types is G1 Therapeutics targeting with COSELA?

G1 Therapeutics is evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers.